ReviewClinical and experimental medicine2021
Emerging treatment strategies for COVID-19 infection.
Review in Clinical and experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
175 citing papers in PubMed, 8 syntheses or guidelines pooled it, 334 citations in OpenAlex.
- Adverse events associated with monoclonal antibodies used for treatment of COVID-19: A systematic review and meta-analysis.British journal of clinical pharmacology · 2025Pooled it
- Role of Metals on SARS-CoV-2 Infection: a Review of Recent Epidemiological Studies.Current environmental health reports · 2023Pooled it
- Safety and efficacy of mesenchymal stem cells in COVID-19 patients: A systematic review and meta-analysis.Immunity, inflammation and disease · 2023Pooled it
- Vitamin C Supplementation for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.Nutrients · 2022Pooled it
- Effect of the COVID-19 Pandemic on Serum Vitamin D Levels in People Under Age 18 Years: A Systematic Review and Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2022Pooled it
- Association of serum C-reactive protein (CRP) and D-dimer concentration on the severity of COVID-19 cases with or without diabetes: a systematic review and meta-analysis.Expert review of endocrinology & metabolism · 2022Pooled it
- The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Pooled it
- The use of complementary and traditional medicine for the treatment of patients with COVID-19: A systematic review.Explore (New York, N.Y.)Pooled it
- Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002-an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults.BMC infectious diseases · 2023Trial
- Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial.BMJ open · 2023Trial
- Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial.Nutrients · 2023Trial
- Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial.Signal transduction and targeted therapy · 2023Trial
- Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.Clinics (Sao Paulo, Brazil) · 2023Trial
- Effect of ArtemiC in patients with COVID-19: A Phase II prospective study.Journal of cellular and molecular medicine · 2022Trial
- Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Trial
- Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population.Viruses · 2022Trial
- Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.Scientific reports · 2022Trial
- Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II.Stem cell research & therapy · 2022Trial
- Trial
- Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study.Blood advances · 2021Trial
115 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new type of coronavirus (COVID-19), SARS-CoV-2 originated from Wuhan, China and has led to a worldwide pandemic. COVID-19 is a novel emerging infectious disease caused by SARS-CoV-2 characterized as atypical pneumonia. As of July 1, 2020, more than 10 million people worldwide had been infected with SARS-CoV-2. The typical manifestations of COVID-19 include fever, sore throat, fatigue, cough, and dyspnoea combined with recent exposure. Most of the patients with COVID-19 have mild or moderate disease, however up to 5-10% present with severe and even life-threatening disease course. The mortality rates are approximately 2%. Therefore, there is an urgent need for effective and specific antiviral treatment. Currently, supportive care measures such as ventilation oxygenation and fluid management remain the standard of care. Several clinical trials are currently trying to identify the most potent drug or combination against the disease, and it is strongly recommended to enroll patients into ongoing trials. Antivirals can be proven as safe and effective only in the context of randomized clinical trials. Currently several agents such as chloroquine, hydroxychloroquine, favipiravir, monoclonal antibodies, antisense RNA, corticosteroids, convalescent plasma and vaccines are being evaluated. The large numbers of therapeutic interventions aim to define the most efficacious regimen. The aim of this article is to describe the treatment strategies that have been used for COVID-19 patients and review all the available literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.